688073 Bide Pharmatech
- 49.28
- -2.02-3.94%
Bide Pharmatech News
Bide Pharmaceutical (688073.SH): Plans to launch the 2024 restricted Stocks incentive plan.
On December 20, Gelonghui reported that Bida Pharmaceuticals (688073.SH) announced its 2024 restricted stock incentive plan, which plans to grant a total of 2.554024 million shares of restricted stock to incentive targets, accounting for approximately 2.81% of the company's total share capital of 90.882948 million shares as of the date of the announcement of this incentive plan draft. A total of 65 individuals are involved in the initial grant of this incentive plan, with the granting price for the restricted stock set at 24.96 yuan per share, meaning that once the granting conditions and vesting conditions are met, the incentive targets can purchase company stock at the price of 24.96 yuan per share.
These 4 Measures Indicate That Bide Pharmatech (SHSE:688073) Is Using Debt Reasonably Well
Bidang Pharmaceutical (688073.SH): The actual controller Dai Lan has proposed that the company repurchase shares again.
Gelonghui, on November 25, reported that Bid Pharmaceutical (688073.SH) announced that the company's board of directors received a letter from Mrs. Dai Lan, the actual controller, chairman, and general manager of the company, on November 24, 2024, proposing that Shanghai Bid Pharmaceutical Technology Co., Ltd. buy back a portion of its issued ordinary shares (A-shares) through the centralized bidding trading method in the Shanghai Stock Exchange trading system. The repurchased shares will be used for the company's stock-based incentive plan or employee stock ownership plan, or to cancel and reduce the company's registered capital. The total amount of funds for the buyback will not be less than 50 million yuan.
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Bede Pharmaceuticals (688073.SH) released its performance for the first three quarters, with a net income of 83.85 million yuan, a year-on-year decrease of 26.05%.
Bide Pharmaceutical (688073.SH) disclosed its third quarter report for 2024. During the reporting period, the company achieved revenue of 8.1...
BiDe Pharmaceutical (688073.SH): The net income in the first three quarters was 83.8539 million yuan, a year-on-year decrease of 26.05%.
GElonghui Oct. 23 - Bide Pharmaceuticals (688073.SH) announced that the company's revenue in the first three quarters was 0.811 billion yuan, a year-on-year increase of 0.79%; net income attributable to shareholders of the listed company was 83.8539 million yuan, a year-on-year decrease of 26.05%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 72.3904 million yuan, a year-on-year decrease of 40.18%; basic earnings per share were 0.94 yuan.
Intensifying competition in the domestic CRO market is eroding profits, BiDe Pharmaceutical claims it will strengthen its overseas market | Direct hit earnings conference
①Due to factors such as the slowdown in investment and financing for innovative drugs, increased competition among CRO companies, BeiDe Medicine's domestic revenue continues to decline, dragging down overall performance and leading to a sharp decrease in net income; ②In contrast, overseas market revenue remains growth, BeiDe Medicine's director, Dai Lan, revealed that there will be corresponding increase in overseas market BD personnel to carry out promotional work in the future.
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Market Cap Increased by CN¥589m, Insiders Receive a 48% Cut
Bide Pharmaceutical (688073.SH): 0.9088 million shares of restricted shares will be unlocked on October 11th.
On September 26, GeLongHui announced that BiDe Pharmaceutical (688073.SH) disclosed that the total number of stocks listed this time is 0.9088 million shares. The date of this stock listing is October 11, 2024.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Bi De Pharmaceutical (688073.SH) released its half-year performance with a net income of 51.8391 million yuan, a year-on-year decrease of 38.15%.
BiDe Pharmaceutical (688073.SH) released its 2024 interim report, with a revenue of 0.532 billion yuan...
BiDe Pharmaceutical (688073.SH): The net income in the first half of the year was 51.8391 million yuan, a year-on-year decrease of 38.15%.
On August 28, Bairui Pharmacy (688073.SH) announced its semi-annual report. The company achieved a revenue of 532.2073 million yuan during the reporting period, a year-on-year growth of 1.83%. The net income attributable to the parent company was 51.8391 million yuan, a year-on-year decrease of 38.15%. Overseas income continued to grow rapidly, and the proportion of overseas income continued to increase. In terms of revenue during the reporting period, overseas income amounted to 299.3019 million yuan, accounting for 56.24%, compared to 265.6107 million yuan, accounting for 50.83% in the same period last year. The overseas income in the first half of 2024 increased year-on-year.
Bide Pharmaceutical (688073.SH) has repurchased 2.81% of its shares for a total cost of 99.99 million yuan.
On July 8th, Gelunhui reported that as of July 5, 2024, Bi De Pharmaceutics (688073.SH) used centralized bidding trading to repurchase a total of 2,554,024 shares of the company's stock, accounting for 2.8102% of the total share capital. The highest repurchase price was 52.99 yuan/share, the lowest price was 28.63 yuan/share, the average repurchase price was 39.15 yuan/share, and the total amount of funds paid was RMB 99,991,734.50 (excluding transaction fees). The company's repurchase amount has reached the lower limit of the repurchase funds in the repurchase program and has not exceeded the total repurchase funds.
Bide Pharmaceutical (688073.SH): Dai Lan accumulatively increased the shareholding of the company by 2.5572 million yuan.
On June 28, Gelunhui announced that Ms. Dai Lan has accumulated 70,090 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding from January 24, 2024 to June 27, 2024. The shareholding accounts for 0.0771% of the total share capital of the company, and the total shareholding amount is RMB 2.5572 million (excluding transaction costs). It has exceeded the lower limit amount of RMB 2.5 million for this shareholding plan, and this shareholding plan has been fully implemented.
Bi De Pharmaceutical (688073.SH): Dinghua Yongchuang partners meeting reviewed and approved the resolution to dissolve and liquidate the partnership enterprise.
On June 18th, Gelunhui reported that Bidet Pharmaceuticals (688073.SH) recently received a notice from shareholder Dinghua Yongchuang to dissolve and liquidate the partnership enterprises at the Dinghua Yongchuang partner meetings. Dinghua Yongchuang will apply to the Shanghai branch of China Securities Depository and Clearing Corporation Limited for non-transaction equity transfer matters of its holding company's shares. After this change in equity, the number of shares held by relevant shareholders and concerted actors is 10,110,685 shares, and the proportion of the company's total share capital held decreased from 12.76% to 11.12%.
BeiDe Pharmaceutical (688073.SH) will distribute cash dividends for the year 2023 on June 26, with a dividend of 0.9 yuan per share.
BiDe Pharmaceutical (688073.SH) announced that it will issue the 2023 annual report on June 26, 2024...
Bide Pharmaceutical (688073.SH): Has repurchased 2.3426% of the company's shares.
On June 4th, Gelonhui reported that Bi De Pharmaceutical (688073.SH) has announced that as of May 31, 2024, the company has cumulatively repurchased 2,129,043 shares of the company through the Shanghai Stock Exchange trading system by means of centralized competitive bidding, accounting for 2.3426% of the total share capital of 90,882,948 shares. The highest repurchase price was 52.99 yuan/share and the lowest price was 31.01 yuan/share. The total amount of the transaction was 87,420,246.76 yuan (excluding transaction fees).
No Data
